Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Holdings Lifted by Swedbank AB

Swedbank AB grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 53.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,107,243 shares of the medical equipment provider's stock after buying an additional 385,000 shares during the period. Swedbank AB owned 1.59% of Lantheus worth $99,054,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Signaturefd LLC grew its holdings in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 92 shares during the period. UMB Bank n.a. boosted its position in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares during the period. GAMMA Investing LLC raised its position in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after purchasing an additional 146 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the third quarter worth about $25,000. Finally, CWM LLC grew its stake in shares of Lantheus by 63.0% in the third quarter. CWM LLC now owns 750 shares of the medical equipment provider's stock valued at $82,000 after buying an additional 290 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the company's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of analyst reports. JMP Securities reiterated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial reaffirmed a "buy" rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $131.86.

Lantheus Stock Performance

Shares of Lantheus stock traded down $0.50 on Thursday, reaching $92.04. 323,755 shares of the company were exchanged, compared to its average volume of 745,904. The firm has a market cap of $6.40 billion, a price-to-earnings ratio of 15.30 and a beta of 0.46. Lantheus Holdings, Inc. has a 1-year low of $51.79 and a 1-year high of $126.89. The company's 50-day moving average is $91.90 and its two-hundred day moving average is $100.07.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.